[1] Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee[J]. J Hypertens, 1999, 17(2):151-183. [2] Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy[J]. Am J Hypertens, 2004, 17(7):590-596. [3] Chien KL, Chao CL, Su TC. Bioavailability study of fixeddose tablet versus capsule formulation of amlodipine plus benazepril:a randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers[J]. Curr Ther Res Clin Exp, 2005, 66(2):69-79. [4] Gatlin M, Jarrett WG, Nwose OM. Efficacy and tolerability of a switch to fixed-dose combination therapy with alodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate:data from the africanamerican subpopulation of a practice-based, open-label study (the logic study)[J]. Curr Ther Res Clin Exp, 2004, 65:138-148. [5] 刘培良, 陈瑶, 安向光, 等. 氨氯地平和苯那普利联合治疗对高血压患者肾功能的影响[J]. 中国心血管病研究杂志, 2005, 3(10):760-762. [6] 贾鸣, 潘琪宏, 朱梓丰, 等. 苯那普利的联合用药选择:左旋氨氯地平与硝本地平缓释片的对比分析[J]. 中国临床药理学与治疗学, 2004, 9(4):470-473. [7] Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy[J]. Blood Press Suppl, 2007, 16(Suppl 1):10-17. [8] Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension[J]. Am J Hypertens, 2004, 17(6):495-501. [9] 朱锦秀, 李见春, 郑青山. 氨氯地平治疗轻、中度高血压有效性与安全性的Meta 分析[J]. 中国临床药理学与治疗学, 2005, 10(2):204-210. [10] Carvalho M, Oliveira GD, Mendes CH, et al. Amlodipine bioequivalence study:quantification by liquid chromatography coupled to tandem mass spectrometry[J]. Biopharm Drug Dispos, 2001, 22(9):383-390. |